BSX - Boston Scientific Corp Stock Price, Fair Value and News

72.72USD-0.71 (-0.97%)Market Closed

Market Summary

USD72.72-0.71

Market Closed

-0.97%

BSX Alerts

3 major insider sales recently.

Big jump in Earnings (Y/Y)

BSX Stock Price

View Fullscreen

BSX RSI Chart

BSX Valuation

Market Cap

108.0B

Price/Earnings (Trailing)

60.96

Price/Sales (Trailing)

7.34

EV/EBITDA

31.65

Price/Free Cashflow

63.58

BSX Price/Sales (Trailing)

BSX Profitability

EBT Margin

14.61%

Return on Equity

8.78%

Return on Assets

4.83%

Free Cashflow Yield

1.57%

BSX Fundamentals

BSX Revenue

Revenue (TTM)

14.7B

Rev. Growth (Yr)

13.78%

Rev. Growth (Qtr)

3.52%

BSX Earnings

Earnings (TTM)

1.8B

Earnings Growth (Yr)

57.01%

Earnings Growth (Qtr)

-2.18%

Breaking Down BSX Revenue

52 Week Range

49.6973.63

(Low)(High)

Last 7 days

2.2%

Last 30 days

7.1%

Last 90 days

12.6%

Trailing 12 Months

38.2%

How does BSX drawdown profile look like?

BSX Financial Health

Current Ratio

1.66

Debt/Equity

0.47

Debt/Cashflow

0.26

BSX Investor Care

Shares Dilution (1Y)

2.26%

Diluted EPS (TTM)

1.19

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	14.7B	0	0	0
2023	13.0B	13.4B	13.8B	14.2B
2022	12.2B	12.3B	12.6B	12.7B
2021	10.1B	11.2B	11.5B	11.9B
2020	10.8B	10.2B	10.1B	9.9B
2019	9.9B	10.1B	10.4B	10.7B
2018	9.3B	9.5B	9.7B	9.8B
2017	8.6B	8.7B	8.8B	9.0B
2016	7.7B	8.0B	8.2B	8.4B
2015	7.4B	7.3B	7.4B	7.5B
2014	7.2B	7.2B	7.3B	7.4B
2013	7.1B	7.1B	7.1B	7.1B
2012	7.6B	7.4B	7.3B	7.2B
2011	7.8B	7.8B	7.8B	7.6B
2010	8.1B	8.0B	7.9B	7.8B
2009	8.0B	8.1B	8.1B	8.2B
2008	0	8.3B	8.2B	8.1B
2007	0	0	0	8.4B

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Boston Scientific Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 02, 2024	sorenson john bradley	sold (taxes)	-138,082	72.03	-1,917	evp, global operations
May 02, 2024	sorenson john bradley	acquired	-	-	4,203	evp, global operations
May 02, 2024	butcher arthur c	acquired	-	-	2,102	evp& grp pres, medsurg & apac
May 02, 2024	butcher arthur c	sold (taxes)	-73,254	72.03	-1,017	evp& grp pres, medsurg & apac
May 01, 2024	carruthers wendy	acquired	82,305	19.3069	4,263	evp, human resources
May 01, 2024	sorenson john bradley	acquired	303,552	17.26	17,587	evp, global operations
May 01, 2024	carruthers wendy	sold	-499,075	71.47	-6,983	evp, human resources
May 01, 2024	sorenson john bradley	sold	-1,257,490	71.501	-17,587	evp, global operations
Apr 26, 2024	ludwig edward j	sold	-719,562	73.2901	-9,818	-
Apr 26, 2024	ludwig edward j	acquired	170,539	17.37	9,818	-

Which funds bought or sold BSX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 06, 2024	Cohen Capital Management, Inc.	unchanged	-	46,992	301,356	0.05%
May 06, 2024	Hilltop National Bank	new	-	138,692	138,692	0.05%
May 06, 2024	NEW YORK LIFE INVESTMENT MANAGEMENT LLC	reduced	-3.39	1,780,620	14,100,100	0.14%
May 06, 2024	Advisory Services Network, LLC	reduced	-11.07	152,963	3,008,650	0.07%
May 06, 2024	TEXAS PERMANENT SCHOOL FUND CORP	reduced	-0.3	3,181,500	20,745,600	0.16%
May 06, 2024	Addison Advisors LLC	new	-	3,220	3,220	-%
May 06, 2024	AIA Group Ltd	reduced	-72.19	-865,029	425,117	0.01%
May 06, 2024	Wealthspire Advisors, LLC	reduced	-21.42	-19,013	256,587	-%
May 06, 2024	Metis Global Partners, LLC	reduced	-0.82	576,267	3,868,320	0.14%
May 06, 2024	Investors Research Corp	reduced	-93.64	-17,639	1,438	-%

Are Funds Buying or Selling BSX?

Are funds buying BSX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BSX

No. of Funds

Unveiling Boston Scientific Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	8.56%	125,449,595	SC 13G/A
Feb 09, 2024	massachusetts financial services co /ma/	3.9%	57,175,974	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 25, 2024	blackrock inc.	8.7%	127,036,665	SC 13G/A
Feb 14, 2023	blackrock inc.	9.6%	137,802,646	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	8.29%	118,773,794	SC 13G/A
Feb 08, 2023	massachusetts financial services co /ma/	5.8%	82,467,469	SC 13G/A
Feb 06, 2023	wellington management group llp	4.03%	57,736,340	SC 13G/A
Jan 24, 2023	blackrock inc.	9.8%	140,116,265	SC 13G/A

Recent SEC filings of Boston Scientific Corp

View All Filings

Date Filed	Form Type	Document
May 07, 2024	144	Notice of Insider Sale Intent
May 06, 2024	4	Insider Trading
May 06, 2024	4	Insider Trading
May 06, 2024	8-K	Current Report
May 02, 2024	4	Insider Trading
May 02, 2024	4	Insider Trading
May 01, 2024	10-Q	Quarterly Report
May 01, 2024	144	Notice of Insider Sale Intent
May 01, 2024	144	Notice of Insider Sale Intent
Apr 29, 2024	DEFA14A	DEFA14A

Peers (Alternatives to Boston Scientific Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	184.5B	40.3B	-4.60%	-4.35%	32.81	4.58	-2.84%	-3.08%
BDX	68.5B	19.7B	-3.65%	-5.69%	51.42	3.48	4.82%	-17.56%
ALGN	21.6B	3.9B	-9.77%	-6.38%	46.66	5.51	5.72%	46.72%
BAX	18.4B	14.9B	-15.25%	-20.81%	6.95	1.24	2.98%	207.68%
MID-CAP
ATR	9.9B	3.5B	5.58%	23.16%	31.71	2.8	6.16%	35.06%
HSIC	9.1B	12.5B	-1.81%	-10.76%	23.5	0.73	-0.61%	-18.83%
BIO	8.2B	2.7B	-13.87%	-26.12%	-12.81	3.06	-4.68%	82.43%
XRAY	5.9B	3.9B	-12.53%	-31.61%	-62.76	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	-0.62%	22.51%	-215.76	8.88	30.82%	65.57%
PDCO	2.3B	6.6B	-0.84%	-0.80%	12.05	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-6.97%	-19.30%	-1.87	0.4	7.94%	-1661.78%
ANIK	420.5M	166.7M	10.85%	9.31%	-5.09	2.52	6.67%	-456.34%
ANGO	245.9M	324.0M	-12.80%	-31.58%	-1.28	0.76	-3.19%	-337.41%
APYX	48.8M	52.3M	-6.00%	-59.48%	-2.61	0.93	17.61%	19.28%
AEMD	3.4M	3.7M	-25.71%	271.43%	-0.27	0.89	5.77%	8.23%

Boston Scientific Corp News

Latest updates

Boston Scientific Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	3.5%	3,856	3,725	3,527	3,599	3,389	3,242	3,170	3,244	3,026	3,127	2,932	3,077	2,752	2,709	2,659	2,003	2,543	2,904	2,707	2,631	2,493
Gross Profit	2.7%	2,648	2,579	2,426	2,542	2,349	2,232	2,191	2,233	2,071	2,155	2,032	2,132	1,858	1,709	1,790	1,212	1,737	2,054	1,930	1,873	1,763
Operating Expenses	-1.1%	1,973	1,995	1,733	2,028	1,797	1,830	1,833	1,810	1,605	1,975	1,645	1,870	1,488	1,659	1,995	1,283	1,591	1,844	1,547	1,489	1,222
S&GA Expenses	-1.1%	1,364	1,379	1,242	1,354	1,215	1,163	1,132	1,165	1,060	1,153	1,066	1,121	1,019	1,027	984	798	978	1,092	1,012	968	869
EBITDA Margin	2.1%	0.25*	0.24*	0.24*	0.22*	0.22*	0.22*	0.20*	0.22*	0.21*	0.21*	0.24*	0.18*	-	-	-	-	-	-	-	-	-
Interest Expenses	7.0%	69.00	65.00	66.00	70.00	65.00	64.00	63.00	64.00	279	87.00	86.00	86.00	82.00	96.00	86.00	91.00	88.00	180	95.00	89.00	109
Income Taxes	11400.0%	115	1.00	105	156	131	256	57.00	85.00	45.00	26.00	64.00	-37.00	-16.00	96.00	-72.00	-33.00	12.00	-4,002	-35.00	-9.00	33.00
Earnings Before Taxes	20.4%	608	505	610	426	444	396	245	345	156	119	483	149	325	307	-227	-181	22.00	-6.00	91.00	145	457
EBT Margin	4.8%	0.15*	0.14*	0.14*	0.11*	0.11*	0.09*	0.07*	0.09*	0.07*	0.09*	0.11*	0.05*	-	-	-	-	-	-	-	-	-
Net Income	-2.2%	493	504	504	270	314	140	188	260	110	95.00	419	186	341	210	-155	-147	11.00	3,996	126	154	424
Net Income Margin	7.7%	0.12*	0.11*	0.09*	0.07*	0.07*	0.06*	0.05*	0.07*	0.07*	0.09*	0.10*	0.05*	-	-	-	-	-	-	-	-	-
Free Cashflow	-102.2%	-15.00	690	508	515	79.00	595	320	202	-179	212	358	537	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	4.4%	36,669	35,136	34,043	33,601	32,892	32,469	31,947	32,189	32,337	32,229	31,877	31,168	30,900	30,777	30,845	30,823	30,113	30,565	26,756	24,309	23,802
Current Assets	25.7%	8,185	6,514	6,504	5,886	5,704	5,760	5,144	5,083	5,065	6,317	6,229	6,758	6,101	6,694	6,160	5,803	4,823	4,699	4,847	6,334	6,234
Cash Equivalents	188.6%	2,496	865	952	426	570	928	338	276	325	1,925	1,947	2,675	2,016	1,995	2,022	1,724	370	607	277	123	139
Inventory	3.1%	2,561	2,484	2,404	2,250	2,050	1,867	1,788	1,752	1,736	1,610	1,603	1,430	1,407	1,351	1,472	1,516	1,628	1,579	1,566	1,300	1,228
Net PPE	1.3%	2,897	2,859	2,635	2,534	2,478	2,446	2,273	2,246	2,265	2,252	2,109	2,082	2,053	2,084	2,064	2,079	2,098	2,079	1,942	1,820	1,782
Goodwill	-0.2%	14,361	14,387	13,608	13,659	13,269	12,920	12,852	12,883	12,949	11,988	11,820	10,874	10,868	9,951	10,137	10,101	10,098	10,176	10,015	8,451	8,179
Current Liabilities	-0.3%	4,916	4,933	4,579	4,562	4,083	3,803	3,549	3,883	4,275	4,274	4,022	4,073	3,393	3,681	3,302	3,108	3,976	4,866	4,254	4,850	4,479
Long Term Debt	11.2%	9,534	8,571	8,386	8,494	8,495	8,915	8,564	8,802	9,067	8,804	8,824	8,847	9,082	9,130	9,325	9,278	9,331	8,592	9,590	7,591	7,590
Shareholder's Equity	4.6%	20,168	19,282	18,886	17.00	178	17,573	17,640	17,251	16,735	16,622	16,462	237	17.00	19,732	15,564	17.00	16.00	270	17,510	17,422	87.00
Retained Earnings	60.4%	1,314	819	315	-189	-450	-750	-876	-1,050	-1,296	-1,392	-1,473	-1,878	-2,050	-2,378	-2,574	-2,405	-2,252	-2,253	-6,249	-6,375	-6,528
Additional Paid-In Capital	0.3%	20,713	20,647	20,573	20,441	20,356	20,289	20,219	20,103	20,043	19,986	19,930	19,817	19,750	19,732	19,687	19,590	17,589	17,561	17,510	17,422	17,374
Shares Outstanding	1.1%	1,468	1,453	1,449	1,441	1,436	1,431	1,432	1,429	1,428	1,422	1,421	1,420	-	-	-	-	-	-	-	-	-
Minority Interest	-2.4%	242	248	243	259	259	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	79,000	-	-	-	-	-	-	-	53,200	-	-	-	50,000	-	-	-	53,100	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-82.9%	164	957	698	658	190	807	470	307	-58.00	478	465	643	284	673	643	269	-77.00	692	502	292	350
Share Based Compensation	6.8%	63.00	59.00	59.00	60.00	55.00	55.00	58.00	55.00	52.00	49.00	51.00	47.00	47.00	42.00	40.00	46.00	42.00	41.00	42.00	38.00	36.00
Cashflow From Investing	72.9%	-285	-1,053	-197	-840	-484	-183	-225	-29.00	-1,574	-461	-1,207	-	71.00	-147	-129	-59.00	-76.00	-49.00	-3,962	-620	-410
Cashflow From Financing	10360.0%	1,569	15.00	16.00	43.00	-69.00	1.00	-199	-344	-6.00	-8.00	6.00	2.00	-95.00	-819	-249	1,105	256	-724	1,314	256	2,127
Dividend Payments	-	-	-	-	14.00	14.00	13.00	14.00	14.00	14.00	13.00	14.00	14.00	14.00	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BSX Income Statement

2024-03-31

Consolidated Statements of Operations (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net sales	$ 3,856	$ 3,389
Cost of products sold	1,209	1,040
Gross profit	2,648	2,349
Operating expenses:
Selling, general and administrative expenses	1,364	1,215
Research and development expenses	366	337
Royalty expense	10	11
Amortization expense	214	203
Contingent consideration net expense (benefit)	17	12
Restructuring net charges (credits)	3	20
Operating expenses	1,973	1,797
Operating income (loss)	675	552
Other income (expense):
Interest expense	(69)	(65)
Other, net	2	(43)
Income (loss) before income taxes	608	444
Income tax expense (benefit)	115	131
Net income (loss)	493	314
Preferred stock dividends	0	(14)
Net income (loss) attributable to noncontrolling interests	(1)	0
Net income (loss) attributable to Boston Scientific common stockholders	$ 495	$ 300
Net income (loss) per common share — basic	$ 0.34	$ 0.21
Net income (loss) per common share — diluted	$ 0.33	$ 0.21
Weighted-average shares outstanding
Basic	1,468.4	1,435.8
Diluted	1,481.7	1,446.0

BSX Balance Sheet

2024-03-31

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 2,329	$ 865
Trade accounts receivable, net	2,304	2,228
Inventories	2,561	2,484
Prepaid income taxes	319	315
Other current assets	671	621
Total current assets	8,185	6,514
Property, plant and equipment, net	2,897	2,859
Goodwill	14,361	14,387
Other intangible assets, net	5,839	6,003
Deferred tax assets	3,792	3,841
Other long-term assets	1,596	1,531
TOTAL ASSETS	36,669	35,136
Current liabilities:
Current debt obligations	1,085	531
Accounts payable	921	942
Accrued expenses	2,083	2,646
Other current liabilities	827	814
Total current liabilities	4,916	4,933
Long-term debt	9,534	8,571
Deferred income taxes	132	134
Other long-term liabilities	1,919	1,967
Commitments and contingencies
Stockholders’ equity
Preferred stock, $0.01 par value - authorized 50,000,000 shares - 0 shares issued as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.01 par value - authorized 2,000,000,000 shares - issued 1,733,293,885 shares as of March 31, 2024 and 1,729,000,224 shares as of December 31, 2023	17	17
Treasury stock, at cost - 263,289,848 shares as of March 31, 2024 and December 31, 2023	(2,251)	(2,251)
Additional paid-in capital	20,713	20,647
Retained earnings	1,314	819
Accumulated other comprehensive income (loss), net of tax	132	49
Total stockholders’ equity	19,926	19,282
Noncontrolling interests	242	248
Total equity	20,168	19,530
TOTAL LIABILITIES AND EQUITY	$ 36,669	$ 35,136
Preferred Stock, Shares Issued	0	0

About Boston Scientific Corp

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, that uses in the treatment of coronary artery disease and aortic valve conditions. Further, it provides stents, balloon catheters, guidewires, atherectomy, and thrombectomy systems to treat arterial and venous diseases; and peripheral embolization devices, radioactive microspheres, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

CEO	Mr. Michael F. Mahoney
WEBSITE	bostonscientific.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	45000

Boston Scientific Corp Frequently Asked Questions

What is the ticker symbol for Boston Scientific Corp? What does BSX stand for in stocks?

BSX is the stock ticker symbol of Boston Scientific Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Boston Scientific Corp (BSX)?

As of Tue May 07 2024, market cap of Boston Scientific Corp is 107.96 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BSX stock?

You can check BSX's fair value in chart for subscribers.

What is the fair value of BSX stock?

You can check BSX's fair value in chart for subscribers. The fair value of Boston Scientific Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Boston Scientific Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BSX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Boston Scientific Corp a good stock to buy?

The fair value guage provides a quick view whether BSX is over valued or under valued. Whether Boston Scientific Corp is cheap or expensive depends on the assumptions which impact Boston Scientific Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BSX.

What is Boston Scientific Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, BSX's PE ratio (Price to Earnings) is 60.96 and Price to Sales (PS) ratio is 7.34. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BSX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Boston Scientific Corp's stock?

In the past 10 years, Boston Scientific Corp has provided 0.192 (multiply by 100 for percentage) rate of return.